Investor Presentaiton

INVESTOR 20 DAY 23 A new category of test will address the unmet need for patient preference 7 out of 10 Individuals who had a stool test would NOT choose stool again¹ Ⓒ 5 to 1 Unscreened individuals prefer blood over stool¹ D 90% Patient adherence to Shield LDT in >10K patients across >1,000 clinics² GUARDANT™ 1.2022 Patient Segmentation Market Research Survey, conducted by Guardant Health 2. Guardant data on file 116

View entire presentation